Unicycive Therapeutics appoints Sara Kenkare-Mitra to board of directors

Unicycive Therapeutics (UNCY) announced the appointment of Sara Kenkare-Mitra, to the Company’s Board of Directors, effective September 6. As a veteran of the biotech and pharmaceutical industry, we believe Sara’s leadership and experience in drug development spanning more than 25 years will significantly help bolster Unicycive’s future growth. Sara Kenkare-Mitra, is currently President and Head of Research and Development at Alector (ALEC) where she leads all aspects of the company’s R&D efforts in neurodegeneration, including oversight of the research, development, clinical, manufacturing, regulatory, and related functions. Prior to joining Alector, Kenkare-Mitra held roles of increasing responsibility at Genentech over the course of 23 years serving most recently as Senior Vice President, Development Sciences in Genentech’s research and early development unit. During her tenure at Genentech, she led a large, integrated global organization of approximately 650 employees, and played a key role in the filing of more than 100 Investigational New Drug/clinical trial applications around the world, and the approval of 11 medicines for diverse diseases, including cancers and neurological diseases. Her team also enabled the successful development and approval of over 15 companion diagnostics.